SCHEMBL3275841

SCHEMBL3275841

O=C1CC(=O)C2=C(C1=O)C(=O)c1ccccc1C2=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.52
BCHE P06276 2/20 0.52
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
CDC25B P30305 2/20 0.50
MAPT P10636 6/20 0.48
RAB9A P51151 5/20 0.48
NPC1 O15118 4/20 0.48
MAOA P21397 3/20 0.48
S100A4 P26447 3/20 0.48
LMNA P02545 3/20 0.48
NPSR1 Q6W5P4 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
APAF1 O14727 2/20 0.48
TDP2 O95551 2/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 2/20 0.48
POLB P06746 2/20 0.48
BLM P54132 2/20 0.48
CES2 O00748 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14003716 0.82 CDC25B (0.73) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL1670775 0.80 CES1 (0.62) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL11290381 0.78 CES1 (0.60) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL11293121 0.78 CES1 (0.60) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL11287850 0.78 CES1 (0.60) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL88188 0.73 CES1 (0.52) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL29353628 0.73 CES1 (0.52) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL3498908 0.73 MEN1 (0.52) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL29411070 0.73 MEN1 (0.52) CES1BCHEMEN1KMT2ACDC25B
SCHEMBL8909389 0.71 MEN1 (0.50) CES1BCHEMEN1KMT2ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2207750-A1 STABILIZATION OF HYDROXYLAMINE CONTAINING SOLUTIONS AND METHOD FOR THEIR PREPARATION EKC Technology, INC. (US) 2010-07-21 EP disclosed
US-7696377-B2 Stabilizer and method for stabilizing hydroxylamine, and stabilized hydroxylamine solution SHOWA DENKO K.K. (JP) 2010-04-13 US disclosed
WO-2009058273-A1 STABILIZATION OF HYDROXYLAMINE CONTAINING SOLUTIONS AND METHOD FOR THEIR PREPARATION EKC TECHNOLOGY, INC. (US) 2009-05-07 WO disclosed
US-20090112024-A1 STABILIZATION OF HYDROXYLAMINE CONTAINING SOLUTIONS AND METHOD FOR THEIR PREPARATION EKC TECHNOLOGY, INC. 2009-04-30 US disclosed
US-7491846-B2 Process for producing hydroxylamine SHOWA DENKO K.K. (JP) 2009-02-17 US disclosed
US-20090043125-A1 STABILIZER AND METHOD FOR STABILIZING HYDROXYLAMINE, AND STABILIZED HYDROXYLAMINE SOLUTION SHOWA DENKO K.K. (JP) 2009-02-12 US disclosed
US-20080193362-A1 Process for Producing Hydroxylamine SHOWA DENKO K.K. (JP) 2008-08-14 US disclosed
WO-2007049663-A1 STABILIZER AND METHOD FOR STABILIZING HYDROXYLAMINE, AND STABILIZED HYDROXYLAMINE SOLUTION SHOWA DENKO K.K. (JP) 2007-05-03 WO disclosed
WO-2006062178-A2 STABILIZER FOR HYDROXYLAMINE, METHOD FOR STABILIZING HYDROXYLAMINE, AND STABILIZED HYDROXYLAMINE SOLUTION SHOWA DENKO K.K. (JP) 2006-06-15 WO disclosed
EP-1663862-A2 PROCESS FOR PRODUCING HYDROXYLAMINE Showa Denko K.K. (JP) 2006-06-07 EP disclosed
WO-2005016817-A2 PROCESS FOR PRODUCING HYDROXYLAMINE SHOWA DENKO K. K. (JP) 2005-02-24 WO disclosed
EP-0103381-B1 SUBSTITUTED ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONES WARNER-LAMBERT COMPANY (US) 1987-09-23 EP disclosed
EP-0147639-A2 Stabilized solutions of hydroxyl amine or salts thereof BASF Aktiengesellschaft (DE) 1985-07-10 EP disclosed
EP-0081777-A2 Process to produce vinyl chloride polymers HOECHST AKTIENGESELLSCHAFT (DE) 1983-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090112024-A1 STABILIZATION OF HYDROXYLAMINE CONTAINING SOLUTIONS AND METHOD FOR THEIR PREPARATION HNMT, HMOX2, EGLN2 CES1 2161/4885BCHE 1118/4885MEN1 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.